Applied Clinical Trials: When is it Time to Kill Your Drug?

July 27, 2018

It can be hard for drug makers to pull the plug on a drug in development, even when all signs indicate they should – resulting in many drugs getting past the preclinical floodgates, only to fail. The mistake: Not having a clinical strategy from the get-go.

A smart, defined clinical strategy sets objective expectations at the beginning of a drug’s development for when and on what criteria development will be terminated. This forces drug developers to ask, “Why are we creating this drug in the first place?”

The answer—and the true drug development opportunity—lies in an understanding of the best available science and patient target(s) for the drug.

Before you take your drug to the point of no return, learn more about TD2’s insight from president and CEO, Stephen Gately, on how to be more strategic from the start in Applied Clinical Trials.

Top Trends in ADC Drug Development

Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic ...

Read more +

Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation

In the landscape of glioblastoma multiforme (GBM) research, the utilization of Orthotopic GBM Patient-Derived Xenograft (PDX) models stands as a ...

Read more +

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2's Most Recent Studies

The fight against Glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer, hinges on the development and use of advanced ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.